Late-breaking results from the STRATIS (Systematic Evaluation of Patients Treated with Neurothrombectomy Devices for Acute Ischemic Stroke) registry re-affirm the benefits of mechanical thrombectomy that have been demonstrated in the four pivotal trials. STRATIS examined the impact of treatment delays on patient outcomes when treated with Medtronic’s Solitaire stent retriever and intravenous tissue plasminogen activator (IV-tPA), if eligible. Among 984 patients, 64 percent were treated with the Solitaire stent retriever and IV-tPA and 36 percent were treated with the Solitaire stent retriever alone. The study found that interhospital transfer was associated with significant delays to treatment and significantly lower chance of functional independence at 90 days (60.0 percent vs. 52.2 percent. Further, those treated via balloon guide catheter (BGC) had higher rates of functional independence at 90 days (61.8 percent vs. 50.2 percent) with fewer passes (1.7 vs. 2.0) than patients treated via distal access catheter.Next Story
ISC 2017: STRATIS Registry Re-Affirms Benefits of Mechanical Thrombectomy from Pivotal Acute Ischemic Stroke Trials
Thursday, February 23, 2017
You must be logged in to leave a comment.